Stabilitech’s stabilization technology means that potentially the quantity of antigen needed to elicit a protective response is reduced by 2 orders of magnitude which would enable antigen from all relevant HA sub-types to be included in the vaccine dose in a manageable tolerable amount.
Stabilitech’s VZV vaccine uses the OKA vaccine strain. It has highly enhanced thermal stability at room temperature giving several hours with minimal loss of titre; additionally, it suffers lower losses on lyophilization than any published results. Once dried, the virus demonstrates enhanced stability with minimal losses observed over at least 7 weeks at 25°C. Finally, upon reconstitution with Stabilitech excipient mixes the virus remains in a state of elevated stability.
Butyrylcholinesterase (BChE) is a naturally occurring protein found in minute quantities in human blood (2 mg/liter). BChE functions as a natural bioscavenger, like a sponge, to absorb and degrade poisons (e.g. nerve agents) before they cause neurological damage.
Stabilitech is in the unique position of being able to deliver reproducible doses of infectious non replicating viral vectors to the luminal surface of the intestinal mucosa. Once the epithelial lining cells are infected they can produce proteins which can accumulate in the blood. The proteins can be expressed for several days but if necessary further doses of vector can be administered to extend the period over which the cells express the protein of interest.